NCT06331377 Clinical and Molecular Characteristics of Histiocytic Disorders
| NCT ID | NCT06331377 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Histiocytic Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2017-07-27 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2017-07-27 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done to collect medical and personal histories as well as a samples of blood, other body fluid and/or tumor/disease tissue for current and future research studies on histiocytic disorders.
Eligibility Criteria
Inclusion Criteria: * All patients diagnosed with histiocytic disorders and age ≥1 year Exclusion Criteria: * \< 1 years age
Contact & Investigator
Jithma P. Abeykoon, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic in Rochester
Frequently Asked Questions
Who can join the NCT06331377 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, studying Histiocytic Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06331377 currently recruiting?
Yes, NCT06331377 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT06331377 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06331377 clinical trial?
NCT06331377 is sponsored by Mayo Clinic. The principal investigator is Jithma P. Abeykoon, MD at Mayo Clinic in Rochester. The trial plans to enroll 500 participants.